NGS-Based RNA-Sequencing Market Growth Opportunities and Forecast by 2027

The NGS-based RNA seq market was valued at US$ 1,414.59 million in 2018 and it is projected to reach US$ 7,984.90 million in 2027; it is expected to grow at a CAGR of 19.3% from 2018 to 2027.

The NGS based RNA seq is done without a reference sequence for the strand-specific libraries that are being profiled for the rare and novel therapeutics. It is highly revolutionized study of the transcriptome which is highly sensitive and accurate for the measurement of the expression all over the transcriptome. The NGS based RNA seq provides researchers with visibility for previously undetected changes occurring in disease states, in response to therapeutics caused by different environmental conditions. In addition, this technique enables researchers to detect the known and unknown features in single assay. Moreover it assists in detecting the gene fusions, single nucleotide variants, transcript isoforms and other features without the restriction of prior data. The growth of the global NGS-based RNA seq market is attributed to the reduced cost of genome sequencing, advancements in sequencing technology and next generation sequencing for cancer. However, risks related to genetic data and high cost of NGS instruments are the major factor hindering the market growth.

The global NGS-based RNA seq market is expected to witness substantial growth post-pandemic. The COVID-19 has affected economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. The COVID-19 crisis has overburdened public health systems in many countries and highlighted the strong need for sustainable investment in health systems. As the COVID-19 pandemic progresses, the healthcare industry is expected to see a drop in growth. The life sciences segment thrives due to increased demand for invitro diagnostic products and rising research and development activities worldwide. However, the medical technologies and imaging segment is witnessing drop in sales due to a smaller number of surgeries being carried out and delayed or prolonged equipment procurement. Additionally, virtual consultations by healthcare professionals are expected to become the mainstream care delivery model post-pandemic. With telehealth transforming care delivery, digital health will continue to thrive in coming years. In addition, disrupted clinical trials and the subsequent delay in drug launches is also expected to pave the way for entirely virtual trials in the future. New technologies such as mRNA is expected to emerge and shift the pharmaceutical industry and market is also expected to witness more vertical integration and joint ventures in coming years.

Lucrative Regions for Global NGS-Based RNA Seq Market

Market Insights

Reduced Cost of Genome Sequencing to Drive Global NGS-Based RNA Seq Market Growth

The growth in the adoption of the next generation sequencing is rising, recently in few years, next generation sequencing price have reduced greatly. For instance, first whole human genome sequencing cost over US$ 3billion in 2001 and it took approximately 15 years for its completion. However, the costs for the same in recent years has reduced to US$1,000 and the process requires less number of days. The cost of sequencing was approximately US$ 3 billion, which dropped down to US$ 10 million in 2006 and as the development in the technologies has increased the prices of sequencing has decreased to US$ 5,000 in 2012. Major market players such as Illumina and Hoffman La Roche Ltd have introduced breakthrough technologies that have enabled in the cost and time reduction in the sequencing.

Moreover, the increase in the service provider companies in the market and their offering for next generation sequencing are cheaper. For instance, Applied Biological Materials, Inc. is an Illumina Certified Service Provider, which offer the next generation sequencing in low cost. Services such as single-end total RNA Sequencing (8 million reads, 1x75bp SE) with minimum two samples is offered in US $375. Likewise paired-end total-end sequencing (8 Million reads, 2x75bp PE) with two samples is performed in US$ 445. Whereas, miRNA seq/Small RNA sequencing (10 million, 1x75 SE) with two samples is offered in US$ 645.

Hence, considering these factors such as advances in the field of next generation sequencing, development in different methods and strategies for sequencing, notable decline in the cost of sequencing, increase in the next generation sequencing service providers are likely to propel the growth of the NGS based RNA seq.

Product & Services -Based Insights

In terms of product & services, the global NGS-based RNA seq market is segmented into sample preparation, sequencing services, sequencing platforms & consumables and data analysis, storage & management. In 2018, the sequencing platforms & consumables segment held largest share of the market. However, the data analysis, storage & management segment is estimated to register the highest CAGR during the forecast period.

Global NGS-Based RNA Seq Market, by Product & Services – 2018 and 2027

Technology -Based Insights

Based on technology, the global NGS-based RNA seq market is segmented into sequencing by synthesis (SBS), nanopore sequencing, ion semiconductor sequencing and single-molecule real-time (SMRT) sequencing. The sequencing by synthesis segment held the largest market share in 2018, also the same segment is estimated to grow at the fastest rate during the forecast period.

Application-Based Insights

In terms of application, the global NGS-based RNA seq market is segmented into diagnostics, drug discovery, precision medicine and others. In 2018, the diagnostics segment held largest share of the market. The same segment is expected to register the highest CAGR during the forecast period.

End User-Based Insights

In terms of end user, the global NGS-based RNA seq market is segmented into hospitals & clinics, academic & research institutes, pharmaceutical & biotechnology companies and other. The academic & research institutes segment held the largest share of the market in 2018, and the hospitals & clinics segment is estimated to register the highest CAGR during the forecast period.

Published Report - NGS-Based RNA-Sequencing Market: Strategic Insights

The global NGS-based RNA seq market players are adopting the product launch and expansion strategies to cater to changing customer demands worldwide, which also allows them to maintain their brand name globally.

Global NGS-Based RNA Seq Market – by Product & Services

• Sample Preparation

• Method

• Manual Method
• Automated Method

• Workflow Step

• Library Preparation & Target Enrichment
• Fragmentation, End Repair & Size Selection
• Quality Control

• Sequencing Services
• Sequencing Platform & Consumables
• Data Analysis, Storage & Management

Global NGS-Based RNA Seq Market – by Technology

• Sequencing By Synthesis
• Nanopore Sequencing
• Ion Semiconductor Sequencing
• Single-Molecule Real-Time (SMRT) Sequencing

Global NGS-Based RNA Seq Market – by Application

• Diagnostics
• Drug Discovery
• Precision Medicine
• Others

Global NGS-Based RNA Seq Market – by End- User

• Hospitals & Clinics
• Research Centers and Academic & Government Institutes
• Biotechnology & Pharmaceutical Companies
• Others

Global NGS-Based RNA Seq Market – by Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • France
  • Germany
  • Italy
  • UK
  • Spain
  • Rest of Europe
• Asia Pacific (APAC)
  • China
  • India
  • South Korea
  • Japan
  • Australia
  • Rest of APAC
• Middle East & Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of MEA
• South America and Central America (SCAM)
  • Brazil
  • Argentina
  • Rest of SCAM

Company Profiles

• Thermo Fisher Scientific Inc.
• Illumina Inc.
• Pacific Biosciences of California, Inc.
• F. Hoffman-La Roche Ltd
• Agilent Technologies
• BGI
• Oxford Nanopre Technologies
• Eurofins Scientific
• Qiagen
• Perkinelmer Inc.

Published Report - NGS-Based RNA-Sequencing Market Players Density: Understanding Its Impact on Business Dynamics

The Published Report - NGS-Based RNA-Sequencing Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.